Chroma Medicine, Inc.

Venture capital mega-rounds of $100m or more have surged in 2024 and the trend has continued in December, with announcements on 19 December that Ottimo Pharma’s series A round brought in more than $14

Scribe Therapeutics is one of a new generation of CRISPR-based gene-editing companies, and believes its in vivo CRISPR X-Editing (XE) technology could be the most efficient yet. Co-founded by CRISP

Epic Bio has presented early data from its non-cutting CRISPR technology which aims to overcome limitations of existing gene therapies and turn on or off disease-related genes. The company was launche

After what seemed like a relatively quiet stretch for venture capital mega-rounds of $100m or more, the pace of large VC financings has picked up in March with five big rounds announced already this m